NCT04297748 : A Bioimaging Study of 89Zr-M7824 PET Scans in Patients With Advanced or Metastatic NSCLC Receiving M7824 Alone or in Combination With Chemotherapy

Male or<br/>FemaleGender Male or
Female

RecruitingStatus Recruiting

Systemic<br/>Therapy TrialTypeSystemic
Therapy Trial

One/TwoPhase One/Two

18+Age Over 18

Lung<br/>CancersCancer LocationLung
Cancers

Systemic therapy | LungNon-Small Cell Lung Cancer

Trial Overview Read MoreRead more

This phase I/II trial will use functional imaging (such as a PET scan) to evaluate the treatment response of non-small cell lung cancer patients receiving an immunotherapy drug (M7824) compared to non-small lung cancer patients receiving standard of care chemotherapy.
 

This trial is treating patients with non-small cell lung cancer.

This is a systemic therapy trial.

You may be able to join this trial if:

  • Your cancer has spread to other parts of the body.

You may be excluded from this trial if:

  • You have been diagnosed with a prior or secondary type of cancer.
  • You have had certain treatments, surgical procedures or drugs.

Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.

Clinical Summary Read MoreRead more

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

Scientific Title

A Bioimaging Study of 89Zr-M7824 PET Scans in Patients With Advanced or Metastatic NSCLC Receiving M7824 Alone or in Combination With Chemotherapy

Other Non-Commercial Sponsor

Olivia Newton-John Cancer Research Institute

Summary

Eligible patients will be enrolled into one of two sequential cohorts. In Cohort A, patients will receive an initial intravenous dose (100mg) of zirconium-89 labelled M7824 on Day 1. Sequential imaging will be performed over one week, to determine the biodistribution of 89Zr-M7824 into the tumour and normal tissues. All patients enrolled in Cohort 1, who remain on trial after Day 14, will receive a 1200mg dose of M7824 every two weeks, begining on Cycle 1 Day 15. Patients will receive another dose on Day 29 and on Day 43, every two weeks until disease progression or unacceptable toxicity. Patients who do not achieve complete remission in the Cohort after 3 doses of M7824 in Cycle 1 may commence treatment with concurrent carboplatin and pemetrexed chemotherapy at a conventional dose. Similar assessments will be undertaken in Cohort B; Cohort A will be used to determine whether or not high-PD-L1 positive disease is required upon entry to Cohort B.

Recruiting Hospitals Read MoreRead more

Olivia Newton-John Cancer Wellness & Research Centre
Heidelberg
Ms Samantha Chakar
samantha.chakar@austin.org.au
03 9496 3088

Trial Overview: General information about a clinical trial. This section provides an overview of who might be able to join this trial and what type of treatment is involved.

Next